<DOC>
	<DOCNO>NCT00491985</DOCNO>
	<brief_summary>This open , randomize , multicenter clinical trial . Objectives : - To describe safety profile 21 day follow primary booster injection . - To describe immune response 21 day primary booster injection formulation . - To describe antibody persistence first vaccination</brief_summary>
	<brief_title>Safety Immunogenicity 2 Formulations Intramuscular A/H5N1 Pandemic Influenza Vaccine Children</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : All subject : Able attend schedule visit comply trial procedure . Children/Adolescents age ≥ 2 year &lt; 18 year : Aged ≥ 2 year &lt; 18 year day inclusion . Informed Consent Form sign one parent another legal representative independent witness parent/legal representative illiterate . For female , inability bear child negative urine pregnancy test ( applicable ) . For female childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ( applicable ) . Infants/toddlers age ≥ 6 month &lt; 2 year : Aged ≥ 6 month &lt; 2 year day inclusion . Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2 kg . Informed Consent Form sign one parent/legally acceptable representative independent witness parent/legally acceptable representative illiterate . Subject complete vaccination accord national immunization schedule . Exclusion Criteria : All subject : Participation another clinical trial 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Systemic hypersensitivity vaccine component history life threaten reaction trial vaccine vaccine contain substance ( egg protein , chick protein , thimerosal , aluminum , neomycin , formaldehyde , octoxinol 9 ) . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive past 3 month . Any vaccination 4 week precede first trial vaccination . Vaccination plan 4 week follow trial vaccination . History H5N1 infection ( confirm either clinically , serologically virologically ) . Known HIV , Hepatitis B ( HBsAg ) Hepatitis C seropositivity . Previous vaccination avian flu vaccine . Subject high risk H5N1 infection trial . Thrombocytopenia bleed disorder contraindicate IM vaccination . Febrile illness ( rectal equivalent temperature ≥ 38.0°C ) day inclusion . Children/Adolescents age ≥ 2 year &lt; 18 year : Breastfeeding mother . Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure ( applicable , depend subject 's age ) . Infants/toddlers age ≥ 6 month &lt; 2 year : History seizure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza A/H5N1 Virus</keyword>
	<keyword>Influenza Pandemic</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
</DOC>